Mounjaro For Weight Loss vs Ozempic for Weight Loss
At My Concierge MD, We think a medical practitioner should choose between Mounjaro and Ozempic after carefully assessing the patient’s medical history, present health, and specific requirements. Every prescription has a unique set of potential side effects and drug interactions that must also be taken into account.
Mounjaro is mostly used to treat excessive blood pressure and heart failure. It works by relaxing blood vessels and lowering the workload on the heart. Ozempic, on the other hand, is used to treat type 2 diabetes by imitating a hormone that helps regulate blood sugar levels.
Both Mounjaro and Ozempic are well-known diabetes medicines. Metformin and canagliflozin are both ingredients in the combo medication Mounjaro. It functions by lowering blood glucose levels and assisting patients in losing body weight. On the other hand, semaglutide is a component of the injectable medication Ozempic. It increases the body’s production of the hormone insulin, which lowers blood sugar levels.
Although both diabetes medications have advantages, research suggests that Ozempic may be preferable to Mounjaro in terms of lowering HbA1c levels. Mounjaro works as a better solution for persons who struggle with weight management.
Obesity and diabetes are becoming increasingly common worldwide, particularly in industrialized countries, and are referred to as the “twin epidemics.” As a result, advanced therapeutic methods are required. Tirzepatide, also known as a ‘twincretin,’ is the only dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonist that can significantly lower glycemic levels and improve insulin sensitivity, as well as reduce body weight by more than 20% and improve lipid metabolism. This innovative anti-diabetic medicine is a synthetic peptide analog of the human GIP hormone with a C20 fatty-diacid component added that, using acylation technology, may bind to albumin to provide a once-week dose of the drug by subcutaneous injection.
Online Prescription for Ozempic or Mounjaro in Los Angeles
Contact us at 310-299-8959 to schedule an in office consult or virtual consult
- Virtual Consult with MD & Nutritionist $450
- 3 Month Supply of the best compounded semaglutide injection $750 ( Special Pricing)
- Follow Ups $200
- Lose 10 – 20% of body fat safely and effectively
Are Ozempic and Mounjaro the same?
While both medications are used to treat type 2 diabetes, their active components and mechanisms of action differ. Ozempic is a brand name for semaglutide, a glucagon-like peptide 1 or GLP 1 receptor agonist that helps regulate blood sugar by increasing insulin secretion while reducing glucagon production. On the other hand, Mounjaro is a brand name for empagliflozin, is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that limits glucose reabsorption in the kidneys, resulting in increased urine glucose excretion and improved control of glycemic levels. Both prescription drugs have possible side effects and may not be appropriate for everyone.
As a result, when taking Type 2 diabetes medication, following your healthcare provider‘s assistance and continually monitoring your blood sugar levels is essential.
What are the similarities between Mounjaro and Ozempic?
While both weight loss medications have proven to be effective in managing blood sugar levels, it is important to note that they have different mechanisms of action and potential side effects.
- Both are weight loss drugs used to treat diabetes and assist lower blood sugar levels.
- They both function by raising insulin synthesis in the body through distinct processes.
- Both medicines may cause nausea, vomiting, and diarrhea.
- They are both prescription drugs that must be administered under the supervision of a physician.
- Because both medications may interact with other drugs, it is critical to advise your doctor of any other medications you are taking.
- In clinical trials, both have been proven to be beneficial in decreasing HbA1c levels.
Mounjaro is a once-daily injection containing the active component albiglutide, while Ozempic is a once-weekly injection.
The new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist MounjaroTM (tirzepatide) injection from Eli Lilly and Company (NYSE: LLY) has been given FDA approval. It is indicated as a supplement to diet and exercise to improve glycemic control in adults with type 2 diabetes. Mounjaro is not recommended for usage in people with type 1 diabetes mellitus and has not been evaluated in patients with a history of pancreatitis.